PDCD1 and melanoma: Cristiani et al. reported that following anti-PD-1 therapies in melanoma patients, the percentage of mature CD117− ILC2s was increased in the periphery, with improved TNFα production of CD117+ ILCs and IL-13 from CD117+ ILC2s [149].